Name

Siegfried Holding

Legal name

Siegfried Holding AG

Website

https://siegfried.ch

Company type

Public

Founded year

1873

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Cell Therapy CDMO (HLAGABAD)

Keywords

• Contract pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Drug substance development
• Finished dosage forms
• Pharmaceutical CDMO services

Headquarters

HQ city

Zofingen

HQ country

Switzerland

HQ region

Europe

Offices15 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Drug Substances (API Manufacturing): Siegfried manufactures active pharmaceutical ingredients and intermediates for pharmaceutical customers through exclusive synthesis, API portfolio products, and reference standards. Revenue is generated through long-term supply agreements and project-based contracts. Net sales in 2025 reached CHF 916.3 million, growing 4.3% in local currencies.
2. Drug Products (Finished Dosage Form Manufacturing): Siegfried manufactures finished dosage forms including oral solid dosage, sterile injectables, ophthalmics, and inhalation products. Revenue comes from manufacturing contracts with pharmaceutical companies. Net sales in 2025 reached CHF 411.6 million, growing 4.3% in local currencies.
3. Development Services: Siegfried provides preclinical and early-phase development services, process development, and optimization. The Siegfried Acceleration Hub in Grafton, Wisconsin supports early-phase CDMO services for drug substances. Revenue from development projects feeds into subsequent manufacturing revenue.
4. Viral Vector Manufacturing (DINAMIQS): DINAMIQS provides end-to-end viral vector development and manufacturing services for cell and gene therapy customers, from R&D through clinical and commercial supply. The cGMP facility opened in September 2025 supports commercial revenue generation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Siegfried is a global Contract Development and Manufacturing Organization (CDMO) that develops and manufactures active pharmaceutical ingredients (APIs/drug substances) and finished dosage forms (drug products) for pharmaceutical and biotechnology customers. The integrated offering covers process development, exclusive synthesis, API portfolio supply, and commercial manufacturing of oral solids, sterile injectables, ophthalmics, inhalation products, and viral vectors for cell and gene therapies.

Product overview

Siegfried Holding is a globally leading Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry. The company operates as a fully integrated CDMO, one of the few organizations that can develop and manufacture both Active Pharmaceutical Ingredients (APIs) and finished dosage forms under one roof. The product portfolio consists of two core pillars: Drug Substances (APIs, exclusive synthesis, API portfolio, reference standards, preclinical development, and alkaloid extraction via Extractas Biosciences) and Drug Products (oral solid dosage forms, sterile injectables, ophthalmics, inhalation products, and viral vectors via DINAMIQS). The offering is complemented by advanced technologies including flow chemistry, spray drying, and fill-finish capabilities. Siegfried serves more than 500 customers globally and operates 16 production sites on four continents (Switzerland, Germany, Spain, France, Malta, USA, China, Australia).

Differentiator

Problem solved

Functional benefit

Brands

• DINAMIQS: A Siegfried company specialized in viral vector design and manufacturing for cell and gene therapies, offering end-to-end manufacturing from molecule design to aseptic drug product filling
• Siegfried Acceleration Hub

Products and services

• Drug Substances (API Manufacturing) Manufacturing of active pharmaceutical ingredients (APIs) and intermediates, including exclusive synthesis, API portfolio products, reference standards, and alkaloid raw materials extraction, for pharmaceutical companies across preclinical through commercial stages.
• Drug Products (Finished Dosage Forms) Contract manufacturing of finished dosage forms including oral solid dosage forms, sterile injectables, ophthalmics, inhalation products, and viral vectors, serving pharmaceutical and biotechnology customers.
• Exclusive Synthesis Custom manufacturing of APIs under exclusive synthesis arrangements for pharmaceutical customers, supporting late-stage clinical and commercial production requirements.
• API Portfolio Portfolio of approved active pharmaceutical ingredients available for commercial supply, comprising approximately 200 of the 1,500 FDA-approved APIs.
• Oral Solid Dosage Forms Contract manufacturing of tablets and capsules as finished drug products at Siegfried's Barcelona-area and other manufacturing sites.
• Sterile Injectables Contract manufacturing of sterile vials, ampoules, pre-filled syringes, and cartridges for injectable drug products, primarily at German manufacturing sites.
• Ophthalmics Contract manufacturing of sterile eye drops and ophthalmic ointments at the El Masnou site in Spain, with ongoing capacity expansion.
• Inhalation Products Contract manufacturing of inhalation drug products including respiratory therapies.
• DINAMIQS Viral Vector Manufacturing End-to-end viral vector design and manufacturing services for cell and gene therapies, from molecule design through R&D to aseptic drug product filling, with cGMP production capacity up to 1,000 L.
• Siegfried Acceleration Hub (Early-Phase CDMO Services) Early-phase contract development and manufacturing services for drug substances, including preclinical and clinical development of APIs, with specialized handling of highly potent APIs (HPAPIs), based at the Grafton, Wisconsin site.
• Reference Standards Supply of API reference standards for pharmaceutical quality control and analytical testing purposes.
• Alkaloid Raw Materials Extraction (Extractas Bioscience) Extraction and processing of alkaloid raw materials for pharmaceutical use, provided through the Extractas Bioscience subsidiary in Tasmania, Australia.

Quantifiable outcome

• More than 90% of revenues derived from commercial-phase products, providing revenue visibility and stability.
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Halo Pharma (SK Capital)minorOthers · 28 January 2026As part of the Noramco Group restructuring, SK Capital divested API-related assets to Siegfried, enabling Halo Pharma to become a stand-alone drug product CDMO. Halo Pharma operates sites in Whippany, New Jersey and Mirabel, Quebec, and is expanding into sterile fill/finish manufacturing services expected in H2 2026.
• SK Capital PartnerscoreOthers · 27 January 2026Siegfried signed binding agreements to acquire the drug substance business of Noramco Group and Extractas Bioscience from an affiliate of SK Capital Partners. The transaction added three manufacturing sites (Noramco Wilmington, Purisys Athens, Extractas Bioscience Tasmania) with ~400 employees, closing May 1, 2026. Following the transaction, SK Capital retained ownership of Halo Pharmaceuticals as a stand-alone drug product CDMO.
• SEAL TherapeuticscoreStrategic or Co-development Partner · 29 September 2025DINAMIQS, a Siegfried company, entered a strategic collaboration with SEAL Therapeutics to support the development and manufacturing of a gene therapy for LAMA2-related muscular dystrophy (a severe childhood-onset disease with no current treatment option). DINAMIQS will leverage its cGMP viral vector manufacturing capabilities and expertise to scale up production of SEAL's innovative gene therapy, enabling the transition from laboratory research toward potential patient treatment. SEAL Therapeutics is a spin-off from the Biozentrum of the University of Basel.

Scale indicators25 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Recipharm AB: Swedish CDMO (private under EQT ownership) offering drug substance and drug product manufacturing, including sterile injectables and inhalation. Comparable European integrated CDMO peer with similar customer mix across small/mid-cap and large pharma.
• Catalent, Inc. US-headquartered CDMO (now owned by Novo Holdings after a 2024 take-private) offering softgel, oral solid, sterile injectables and biologics fill-finish. Overlaps with Siegfried's Drug Products cluster (oral solids, sterile injectables, ophthalmics) and competes for large-pharma outsourcing RFPs.
• Fareva S.A. Privately held French pharmaceutical CDMO offering drug substance and drug product manufacturing across sterile, liquid and topical forms. Comparable European integrated CDMO peer to Siegfried, particularly on Drug Products.
• Halo Pharmaceuticals: US drug product CDMO (still owned by SK Capital following the 2026 Noramco carve-out) specializing in oral solids and expanding into sterile fill/finish. Directly comparable to Siegfried's Drug Products cluster and a named counterparty in the recent SK Capital transaction, making it a tight industry peer.
• Aenova Holding GmbH: German-headquartered CDMO (private, owned by BC Partners) specializing in oral solid dosage forms, sterile liquids and semi-solids. Directly comparable to Siegfried's Drug Products cluster in technology, geographic footprint (DACH region) and customer type.
• CordenPharma International: European CDMO owned by International Chemical Investors Group (ICIG), with capabilities across APIs, peptides, injectables and highly potent compounds. Closely comparable to Siegfried's small-molecule API and sterile injectable businesses, including controlled substance handling.
• Lonza Group AG: Swiss-headquartered global CDMO and the largest pure-play in the space, offering integrated drug substance and drug product services across small molecules, biologics and cell & gene therapy. Directly comparable to Siegfried on geography, integrated model and customer base, but at materially larger scale and broader modality.
• EuroAPI S.A. European API manufacturer spun off from Sanofi in 2022, offering small-molecule API and intermediates production. Comparable to Siegfried's Drug Substances cluster on geography and product type, though more concentrated in legacy Sanofi volumes.
• WuXi STA (WuXi AppTec subsidiary): China-based CDMO providing small-molecule API development and manufacturing plus drug product services. Directly comparable to Siegfried on the Drug Substances cluster, though operating at substantially larger scale and primarily serving global innovators from a China base.
• Cambrex Corporation: US-headquartered CDMO (private under Permira ownership) specializing in small-molecule API development and manufacturing, with a strong controlled substances franchise. Highly comparable to Siegfried's Drug Substances business, particularly the recent Noramco-controlled-substance expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/siegfried_group
• Facebookfacebook.com/SiegfriedHoldingAG
• LinkedInlinkedin.com/company/siegfried-holding-ag

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Siegfried Holding